| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg |
|
||
| Other Sizes |
| Targets |
Heptadecan-9-yl 8-bromooctanoate does not have a specific biological target as a drug; rather, it is a chemical tool used in the construction and modification of lipid nanoparticles. The compound serves as a lipid excipient or linker in nanoparticle formulations. Its bromo functional group can be used for further chemical conjugation or cross-linking reactions, enabling the attachment of targeting ligands, drugs, or imaging agents to the nanoparticle surface. As a lipid component, it contributes to the structural integrity and physicochemical properties of lipid-based delivery systems.
|
|---|---|
| ln Vitro |
In vitro, Heptadecan-9-yl 8-bromooctanoate is not typically evaluated for biological activity as a drug, but rather for its utility in nanoparticle formulation. The compound is used to prepare lipid nanoparticles, which are then characterized for size, polydispersity, zeta potential, drug loading capacity, and release profiles in vitro. The lipid nanoparticles can be tested in cell culture for cellular uptake, cytotoxicity, and transfection or drug delivery efficiency. However, the compound itself does not have specific in vitro pharmacological activity.
|
| ln Vivo |
In vivo, Heptadecan-9-yl 8-bromooctanoate is used as a component of lipid nanoparticles for drug delivery applications. The lipid nanoparticles containing this compound can be administered to animal models to evaluate their biodistribution, pharmacokinetics, and therapeutic efficacy. The compound itself is not a pharmacologically active agent; rather, it serves as a structural component that influences the behavior of the nanoparticle delivery system in vivo.
|
| Enzyme Assay |
There are no specific in vitro enzyme or receptor binding assays for Heptadecan-9-yl 8-bromooctanoate, as it is not a drug targeting a specific biological receptor or enzyme. The compound is a chemical reagent used in formulation chemistry. Characterization of the compound typically involves analytical methods such as NMR, HPLC, and mass spectrometry to confirm identity and purity. Its utility is assessed by its ability to form stable lipid nanoparticles with desired physicochemical properties (size, zeta potential, encapsulation efficiency).
|
| Cell Assay |
There are no specific in vitro cellular assays for Heptadecan-9-yl 8-bromooctanoate as a pharmacologically active compound. However, lipid nanoparticles formulated with this compound can be tested in cell culture models. Typical cell lines used include HEK293, HeLa, or primary cells relevant to the intended therapeutic application. Cells are incubated with nanoparticle formulations containing the compound, and cellular uptake is assessed by fluorescence microscopy or flow cytometry. Cytotoxicity is evaluated using MTT or LDH assays. Drug delivery efficiency is measured by quantifying the delivery of encapsulated cargo (drug or nucleic acid).
|
| Animal Protocol |
There are no specific in vivo animal studies for Heptadecan-9-yl 8-bromooctanoate as a pharmacologically active compound. However, lipid nanoparticles formulated with this compound can be evaluated in animal models. Typical studies involve intravenous or oral administration of nanoparticle formulations to mice or rats, followed by assessment of biodistribution (organ accumulation), pharmacokinetics (plasma concentration vs. time), and therapeutic efficacy in disease models. The compound itself is a formulation excipient rather than an active pharmaceutical ingredient.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Heptadecan-9-yl 8-bromooctanoate are not typically studied as the compound is a formulation excipient rather than a drug. When incorporated into lipid nanoparticles, the pharmacokinetics of the nanoparticle formulation are determined by the overall particle characteristics (size, surface properties, PEGylation) rather than by this individual component. The long alkyl chain suggests high lipophilicity, which would favor partitioning into lipid bilayers and slow release from the injection site. The compound is likely metabolized by esterases to release 8-bromooctanoic acid and heptadecan-9-ol.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Heptadecan-9-yl 8-bromooctanoate is not extensively reported. As a lipid excipient, it is expected to have low toxicity when used in nanoparticle formulations at appropriate concentrations. The compound is for research use only and not for human therapeutic use. Standard toxicity studies for nanoparticle formulations would include assessment of hemocompatibility, cytotoxicity in cell lines, and acute toxicity in rodents. The bromo functional group may be reactive, requiring careful handling. No specific genotoxicity or immunogenicity data are reported.
|
| Additional Infomation |
Heptadecan-9-yl 8-bromooctanoate (CAS 2089253-22-3) is a chemical compound utilized in the construction and modification of lipid nanoparticles. It serves as a building block for lipid-based drug delivery systems, enabling the formulation of nanoparticles with tailored permeability, stability, and drug release properties. The compound features a bromo functional group that allows for further chemical conjugation, making it a versatile tool for attaching targeting ligands or therapeutic payloads to nanoparticle surfaces. It is available for research use only and is not intended for therapeutic applications.
|
| Molecular Formula |
C25H49BRO2
|
|---|---|
| Molecular Weight |
461.56
|
| Exact Mass |
460.291
|
| CAS # |
2089253-22-3
|
| PubChem CID |
126697545
|
| Appearance |
Colorless to light yellow liquid
|
| LogP |
10.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
23
|
| Heavy Atom Count |
28
|
| Complexity |
304
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
KHEPAYMMEKWSAW-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C25H49BrO2/c1-3-5-7-9-12-16-20-24(21-17-13-10-8-6-4-2)28-25(27)22-18-14-11-15-19-23-26/h24H,3-23H2,1-2H3
|
| Chemical Name |
heptadecan-9-yl 8-bromooctanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~216.66 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (5.42 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1666 mL | 10.8328 mL | 21.6657 mL | |
| 5 mM | 0.4333 mL | 2.1666 mL | 4.3331 mL | |
| 10 mM | 0.2167 mL | 1.0833 mL | 2.1666 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
